TY - BOOK PY - 2015 DA - 2015// TI - Value based assessment of drugs ID - ref1 ER - TY - STD TI - National Audit Office. Investigation into the Cancer Drugs Fund. 2015.https://www.nao.org.uk/report/investigation-into-the-cancer-drugs-fund/. UR - https://www.nao.org.uk/report/investigation-into-the-cancer-drugs-fund/ ID - ref2 ER - TY - JOUR AU - Buxton, M. AU - Longworth, L. AU - Raftery, J. AU - Sculpher, M. AU - Towse, A. PY - 2014 DA - 2014// TI - Reforming the Cancer drug fund JO - BMJ VL - 349 UR - https://doi.org/10.1136/bmj.g7276 DO - 10.1136/bmj.g7276 ID - Buxton2014 ER - TY - JOUR AU - Linley, W. G. AU - Hughes, D. A. PY - 2013 DA - 2013// TI - Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in great Britain JO - Health Econ VL - 22 UR - https://doi.org/10.1002/hec.2872 DO - 10.1002/hec.2872 ID - Linley2013 ER - TY - JOUR AU - Dixon, P. AU - Chamberlain, C. AU - Hollingworth, W. PY - 2016 DA - 2016// TI - Did it matter that the Cancer drugs fund was not NICE? A retrospective review JO - Value Health VL - 19 UR - https://doi.org/10.1016/j.jval.2016.04.001 DO - 10.1016/j.jval.2016.04.001 ID - Dixon2016 ER - TY - BOOK PY - 2016 DA - 2016// TI - PMG19 addendum a - final amendments to the NICE technology appraisal processes and methods guides to support the proposed new Cancer drugs fund arrangements ID - ref6 ER - TY - STD TI - McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, et al. Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ. 2010;340 https://doi.org/10.1136/bmj.c1786. ID - ref7 ER - TY - BOOK PY - 2016 DA - 2016// TI - Final evaluation determination: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene ID - ref8 ER - TY - JOUR AU - Boon, W. AU - Martins, L. AU - Koopmanschap, M. PY - 2015 DA - 2015// TI - Governance of conditional reimbursement practices in the Netherlands JO - Health Policy VL - 119 UR - https://doi.org/10.1016/j.healthpol.2014.10.013 DO - 10.1016/j.healthpol.2014.10.013 ID - Boon2015 ER - TY - JOUR AU - Montilla, S. AU - Xoxi, E. AU - Russo, P. AU - Cicchetti, A. AU - Pani, L. PY - 2015 DA - 2015// TI - Monitoring registries at Italian Medicines Agency : fostering access, guaranteeing sustainability JO - Int J Technol Assess Health Care VL - 31 UR - https://doi.org/10.1017/S0266462315000446 DO - 10.1017/S0266462315000446 ID - Montilla2015 ER - TY - JOUR AU - Faulkner, S. D. AU - Lee, M. AU - Qin, D. AU - Morrell, L. AU - Xoxi, E. AU - Sammarco, A. PY - 2016 DA - 2016// TI - Pricing and reimbursement experiences and insights in the European Union and the United States: lessons learned to approach adaptive payer pathways JO - Clinical Pharmacology & Therapeutics VL - 100 UR - https://doi.org/10.1002/cpt.508 DO - 10.1002/cpt.508 ID - Faulkner2016 ER - TY - JOUR AU - Hannah, D. AU - Lautsch, B. PY - 2011 DA - 2011// TI - Counting in qualitative research: why to conduct it, when to avoid it, and when to closet it JO - Journal of Management Enquiry VL - 20 UR - https://doi.org/10.1177/1056492610375988 DO - 10.1177/1056492610375988 ID - Hannah2011 ER - TY - BOOK PY - 2014 DA - 2014// TI - Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (TA316) ID - ref13 ER - TY - BOOK PY - 2015 DA - 2015// TI - Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA338) ID - ref14 ER - TY - BOOK PY - 2016 DA - 2016// TI - Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412) ID - ref15 ER - TY - BOOK PY - 2014 DA - 2014// TI - Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310) ID - ref16 ER - TY - BOOK PY - 2015 DA - 2015// TI - Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371) ID - ref17 ER - TY - BOOK PY - 2016 DA - 2016// TI - Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378) ID - ref18 ER - TY - BOOK PY - 2014 DA - 2014// TI - Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (TA309) ID - ref19 ER - TY - STD TI - NICE. Guide to the methods of technology appraisal 2013. https://www.nice.org.uk/process/pmg9/chapter/foreword. UR - https://www.nice.org.uk/process/pmg9/chapter/foreword ID - ref20 ER - TY - BOOK PY - 2014 DA - 2014// TI - Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307) ID - ref21 ER - TY - BOOK PY - 2015 DA - 2015// TI - Bortezomib for previously untreated mantle cell lymphoma (TA370) ID - ref22 ER - TY - BOOK PY - 2016 DA - 2016// TI - Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384) ID - ref23 ER - TY - STD TI - NICE. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311) 2014. https://www.nice.org.uk/guidance/ta311. UR - https://www.nice.org.uk/guidance/ta311 ID - ref24 ER - TY - BOOK PY - 2014 DA - 2014// TI - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323) ID - ref25 ER - TY - BOOK PY - 2014 DA - 2014// TI - Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321) ID - ref26 ER - TY - BOOK PY - 2015 DA - 2015// TI - Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366) ID - ref27 ER - TY - BOOK PY - 2015 DA - 2015// TI - Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer (TA347) ID - ref28 ER - TY - BOOK PY - 2015 DA - 2015// TI - Idelalisib for treating chronic lymphocytic leukaemia (TA359) ID - ref29 ER - TY - BOOK PY - 2016 DA - 2016// TI - Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381) ID - ref30 ER - TY - BOOK PY - 2015 DA - 2015// TI - Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357) ID - ref31 ER - TY - BOOK PY - 2015 DA - 2015// TI - Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374) ID - ref32 ER - TY - BOOK PY - 2014 DA - 2014// TI - Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319) ID - ref33 ER - TY - BOOK PY - 2015 DA - 2015// TI - Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343) ID - ref34 ER - TY - BOOK PY - 2015 DA - 2015// TI - Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360) ID - ref35 ER - TY - STD TI - NICE. Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322) 2014. https://www.nice.org.uk/guidance/ta322. UR - https://www.nice.org.uk/guidance/ta322 ID - ref36 ER - TY - JOUR AU - Grieve, R. AU - Abrams, K. AU - Claxton, K. AU - Goldacre, B. AU - James, N. AU - Nicholl, J. PY - 2016 DA - 2016// TI - Cancer drugs fund requires further reform JO - BMJ VL - 354 UR - https://doi.org/10.1136/bmj.i5090 DO - 10.1136/bmj.i5090 ID - Grieve2016 ER - TY - BOOK PY - 2018 DA - 2018// TI - Avelumab for merkel cell carcinoma (ID1102) ID - ref38 ER - TY - BOOK PY - 2016 DA - 2016// TI - Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer: managed access agreement ID - ref39 ER - TY - BOOK PY - 2017 DA - 2017// TI - Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492) ID - ref40 ER - TY - CHAP AU - Briggs, A. ED - Drummond, M. F. ED - McGuire, A. PY - 2001 DA - 2001// TI - Handling uncertainty in economic evaluation and presenting the results BT - Economic evaluation in health care: merging theory and practice PB - Oxford University Press CY - Oxford ID - Briggs2001 ER - TY - BOOK AU - Briggs, A. AU - Claxton, K. AU - Sculpher, M. PY - 2006 DA - 2006// TI - Decision modelling for health economic evaluation. Handbooks in health economic evaluation PB - Oxford University Press CY - Oxford ID - Briggs2006 ER - TY - BOOK AU - Gray, A. AU - Clarke, P. AU - Wolstenholme, J. AU - Wordsworth, S. PY - 2011 DA - 2011// TI - Applied methods of cost-effectiveness analysis in health care. Handbooks in HealthEconomic evaluation PB - Oxford University Press CY - Oxford ID - Gray2011 ER - TY - JOUR AU - Bojke, L. AU - Claxton, K. AU - Sculpher, M. AU - Palmer, S. PY - 2009 DA - 2009// TI - Characterizing structural uncertainty in decision analytic models: a review and application of methods JO - Value Health VL - 12 UR - https://doi.org/10.1111/j.1524-4733.2008.00502.x DO - 10.1111/j.1524-4733.2008.00502.x ID - Bojke2009 ER - TY - JOUR AU - Sculpher, M. J. AU - Pang, F. S. AU - Manca, A. AU - Drummond, M. F. AU - Golder, S. AU - Urdahl, H. PY - 2004 DA - 2004// TI - Generalisability in economic evaluation studies in healthcare: a review and case studies JO - Health technology assessment (Winchester, England) VL - 8 ID - Sculpher2004 ER - TY - JOUR AU - Briggs, A. H. AU - Weinstein, M. C. AU - Fenwick, E. A. L. AU - Karnon, J. AU - Sculpher, M. J. AU - Paltiel, A. D. PY - 2012 DA - 2012// TI - Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group–6 JO - Med Decis Mak VL - 32 UR - https://doi.org/10.1177/0272989X12458348 DO - 10.1177/0272989X12458348 ID - Briggs2012 ER - TY - CHAP AU - Sculpher, M. AU - Basu, A. AU - Kuntz, K. AU - Meltzer, D. ED - Neumann, P. J. S. G. ED - Russell, L. B. ED - Siegel, J. E. ED - Ganiats, T. G. PY - 2017 DA - 2017// TI - Reflecting uncertainty in cost-effectiveness analysis BT - Cost-effectiveness in health and medicine (2nd edition) PB - Oxford University Press CY - New York ID - Sculpher2017 ER - TY - BOOK PY - 2017 DA - 2017// TI - Advancing evidence generation for new drugs: IMI GetReal’s Recommendationson real-world evidence ID - ref48 ER - TY - JOUR AU - Kemp, R. AU - Prasad, V. PY - 2017 DA - 2017// TI - Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? JO - BMC Med VL - 15 UR - https://doi.org/10.1186/s12916-017-0902-9 DO - 10.1186/s12916-017-0902-9 ID - Kemp2017 ER - TY - JOUR AU - Ciani, O. AU - Davis, S. AU - Tappenden, P. AU - Garside, R. AU - Stein, K. AU - Cantrell, A. PY - 2014 DA - 2014// TI - Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers JO - Int J Technol Assess Health Care VL - 30 UR - https://doi.org/10.1017/s0266462314000300 DO - 10.1017/s0266462314000300 ID - Ciani2014 ER - TY - JOUR AU - Prasad, V. AU - Kim, C. AU - Burotto, M. AU - Vandross, A. PY - 2015 DA - 2015// TI - The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses JO - JAMA Intern Med VL - 175 UR - https://doi.org/10.1001/jamainternmed.2015.2829 DO - 10.1001/jamainternmed.2015.2829 ID - Prasad2015 ER - TY - JOUR AU - Ciani, O. AU - Buyse, M. AU - Drummond, M. AU - Rasi, G. AU - Saad, E. D. AU - Taylor, R. S. PY - 2017 DA - 2017// TI - Time to review the role of surrogate end points in health policy: state of the art and the way forward JO - Value Health VL - 20 UR - https://doi.org/10.1016/j.jval.2016.10.011 DO - 10.1016/j.jval.2016.10.011 ID - Ciani2017 ER - TY - BOOK PY - 2017 DA - 2017// TI - Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495) ID - ref53 ER - TY - JOUR AU - Claxton, K. AU - Palmer, S. AU - Longworth, L. AU - Bojke, L. AU - Griffin, S. PY - 2012 DA - 2012// TI - Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development JO - Health Technol Assess VL - 16 UR - https://doi.org/10.3310/hta16460 DO - 10.3310/hta16460 ID - Claxton2012 ER -